Dr. Shudong Ma 马树东
Chief Physician, Associate Professor
Department of Medical Oncology, Nanfang Hospital, Southern Medical University, Guangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of lung cancer. Experience in managing esophageal, breast, ovarian, cervical, head and neck, gastric, and colorectal cancers, as well as tumor emergencies. Uses immunotherapy, molecular targeted therapy, and chemotherapy.
Dr. Ma is Deputy Director of the Department of Oncology at Nanfang Hospital. With nearly 30 years of experience, Dr. Ma holds a doctorate in oncology and completed postdoctoral work at Sun Yat-sen University and the Norris Comprehensive Cancer Center, University of Southern California. Dr. Ma has led or participated in nearly 20 research projects and published over 40 papers.
Professional roles
- Vice Chair, Lung Cancer Multidisciplinary Collaboration Committee, Guangdong Chest Disease Society
- Standing Committee Member, Oncology Branch, Guangdong Medical Doctor Association
- Standing Committee Member, Immunology Professional Committee, Guangdong Chest Disease Society
- Member, Esophageal Cancer Professional Committee, Guangdong Anti-Cancer Association
Name order: in Chinese the family name comes first (Ma Shudong). Papers usually list the name as Shudong Ma or Ma S.
Selected publications
25 papers on PubMed matched by name and affiliation; 9 as first or senior author since 2016. Most recent first- or senior-author papers:
- BMC Cancer, 2025 (senior author): The prognostic role of inflammation-based hematologic markers in stage I-III colorectal cancer: a retrospective analysis. PubMed 41291516
- Front Oncol, 2025 (senior author): Linoleic acid drives pulmonary lymphoepithelioma-like carcinoma progression via PPAR-α/TF axis. PubMed 40896442
- Front Immunol, 2024 (senior author): Gut microbiota and pancreatic cancer risk, and the mediating role of immune cells and inflammatory cytokines: a Mendelian randomization study. PubMed 39119339
- Front Microbiol, 2024 (senior author): Immune cells mediated the causal relationship between the gut microbiota and lung cancer: a Mendelian randomization study. PubMed 38765682
- Discov Oncol, 2023 (senior author): Veillonella parvula promotes the proliferation of lung adenocarcinoma through the nucleotide oligomerization domain 2/cellular communication network factor 4/nuclear factor kappa B pathway. PubMed 37452162
- J Cancer Res Clin Oncol, 2023 (senior author): Anti-angiogenic therapy for advanced primary pulmonary lymphoepithelioma-like carcinoma: a retrospective multicenter study. PubMed 35377040
- Bioengineered, 2022 (senior author): Alterations of lung microbiota in patients with non-small cell lung cancer. PubMed 35254206
- Nan Fang Yi Ke Da Xue Xue Bao, 2018 (senior author): [USP33 suppresses lung adenocarcinoma lung cell invasion and metastasis by down-regulating SLIT2/ROBO1 signaling pathway]. PubMed 30187867
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion